GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Other Income (Expense)

iX Biopharma (SGX:42C) Other Income (Expense) : S$-3.02 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Other Income (Expense)?

iX Biopharma's other income expense for the iX Biopharma's pretax income for the six months ended in Dec. 2024 was S$-2.52 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was S$-3.02 Mil.


iX Biopharma Other Income (Expense) Historical Data

The historical data trend for iX Biopharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Other Income (Expense) Chart

iX Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 2.01 -5.14 -1.03 -2.70

iX Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.51 0.48 -2.20 -0.50 -2.52

iX Biopharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$-3.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iX Biopharma  (SGX:42C) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


iX Biopharma Business Description

Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines